drugset / Trial / NCT03605433
Surgical Revascularization Outcomes After Oral Anticoagulation or Antiplatelets
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate whether treatment with oral anticoagulation or oral anticoagulation and aspirin is better than aspirin alone in cardiovascular outcomes and saphenous graft patency in patients submitted to coronary artery bypass graft.
Timeline
- Start
- 2018-12-01
- Primary completion
- 2019-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivaroxaban | Other / unclassified | 2.5 mg | Oral |
| Subject | Rivaroxaban | Other / unclassified | 20 mg | Oral |